Green tea and COX-2 inhibitors combine to slow growth of prostate cancer

Drinking a nice warm cup of green tea has long been touted for its healthful benefits, both real and anecdotal. But now researchers have found that a component of green tea, combined with low doses of a COX-2 inhibitor, could slow the spread of human prostate cancer.

In the March 1 issue of Clinical Cancer Research, researchers from University of Wisconsin-Madison demonstrate that low doses of the COX-2 inhibitor celecoxib, administered with a green tea polyphenol called pigallocatechin-3-gallate (EGCG), can slow the growth of human prostate cancer. Their experiments were performed in cell cultures and in a mouse model for the disease.

“Celecoxib and green tea have a synergistic effect -- each triggering cellular pathways that, combined, are more powerful than either agent alone,” said Hasan Mukhtar, Ph.D., professor of dermatology at the University of Wisconsin and member of Wisconsin’s Paul Carbone Comprehensive Cancer Center. “We hope that a clinical trial could lead to a preventative treatment as simple as tea time.”

Previous research has linked the cyclooxygenase-2 enzyme, commonly known as COX-2, to many cancer types, including prostate cancer, said Mukhtar. Mukhtar and his colleagues have previously shown COX-2 inhibitors like celecoxib (known under the brand name Celebrex™) suppress prostate cancer in animal models. COX-2 inhibitors also have been shown to cause adverse cardiovascular effects when administered at high doses over long durations.

In 2004, Mukhtar and his colleagues demonstrated that green tea polyphenol EGCG has cancer-fighting abilities of its own. Their study, published in Cancer Research, showed that EGCG can modulate the insulin-like growth factor-1 (IGF-1)-driven molecular pathway in a mouse model for human prostate cancer, pushing the cells toward programmed cell death (apoptosis).

“We believed that COX-2 inhibitors may still prove beneficial if used in combination with complementary agents,” Mukhtar said. “Our studies showed that the additive effect of green tea enables us to utilize the cancer-fighting abilities of COX-2 inhibitors, but at lower, safer doses.”

In this latest research, Mukhtar and his colleagues looked at the effects of the two substances on cultured human prostate cancer cells. Alone, both EGCG and NS-398, a COX-2 inhibitor similar to celecoxib, demonstrated the ability to slow cancer cell growth and limit the presence of known cancer-promoting proteins within the cell samples. Together, EGCG and NS-398 suppressed cell growth by an additional 15 to 28 percent.

The researchers repeated the experiment in mouse models of prostate cancer, using celecoxib and an oral suspension of the decaffeinated green tea polyphenol. By using pharmacy-grade celecoxib and actual tea, they had hoped to replicate real-life conditions. “The idea is that it would be easier to get people to drink green tea than it would be to take an additional dietary supplement,” Mukhtar said.

In mice that were not treated with either substance, the tumor volume averaged 1,300 cubic millimeters, whereas mice given either the tea or celecoxib had tumors averaging 835 cubic millimeters and 650 cubic millimeters, respectively. Tumors taken from mice given both agents, however, measured on average a volume of 350 cubic millimeters.

In parallel to tumor growth inhibition, mice that received a combination of green tea and celecoxib registered a greater decrease in prostate specific antigen (PSA) levels compared to that in celecoxib alone or green tea alone treated animals. PSA is a protein produced by the cells of the prostate and is used as a marker for detection and progression of prostate cancer. These results, combined with a marked decrease in the presence of cancer-promoting proteins, offered clear indications that green tea and celecoxib, combined, could be useful in slowing prostate cancer growth, Mukhtar said.

“Prostate cancer typically arises from more than one defect in the cellular mechanics, which means that a single therapeutic might not work fighting a particular cancer long-term,” Mukhtar said. “If tests in human trials replicate these results, we could see a powerful combined therapy that is both simple to administer and relatively cost effective.”

Source: American Association for Cancer Research

Related stories:

MRI spots DCIS in mice
A new magnetic resonance imaging procedure can detect very early breast cancer in mice, including ductal carcinoma in situ (DCIS), a precursor to invasive cancer. Some of the tumors detected were less than 300 microns in diameter, the smallest cancers ever detected by MRI.
Feeding your body's defenses against cancer
David Servan-Schreiber was 31 when he was diagnosed with a walnut-size brain tumor and given 6 months to live. After surgery and chemotherapy, the young neuroscientist asked his oncologist if he should change his diet.
As head and neck cancer risks evolve, more treatment options emerge
Advances in understanding head and neck cancer over the last decade have led to more treatment options and improved quality of life for patients, according to a review published this week in the New England Journal of Medicine.
Coffee may lower risk of uterus cancer: Japan study
Women who drink a lot of coffee may have less risk of developing cancer of the uterus, a Japanese study said Monday.
Probing Question: How do antioxidants work?
Blueberries, pomegranates, green tea and dark chocolate -- these are just some of the antioxidant-rich "superfoods" found in almost any supermarket today. As well as improving our general health, there is growing evidence that diets high in antioxidants may confer some protection against a long list of chronic diseases, including Alzheimer's disease, cancer and even HIV. Given their increasing popularity, the fundamental question bears asking: What exactly are antioxidants, and how do they work in our bodies?
Fruits, vegetables and teas may protect smokers from lung cancer
Tobacco smokers who eat three servings of fruits and vegetables per day and drink green or black tea may be protecting themselves from lung cancer, according to a first-of-its-kind study by UCLA cancer researchers.
Extracts from reishi mushroom and green tea shows synergistic effect to slow sarcoma
Both the reishi mushroom (Ganoderma lucidum; Lingzhi) and green tea have long held a place in traditional medicine in China and other Asian countries, for the general promotion of health and long life and for the treatment of specific diseases. More recent scientific studies have confirmed that both enhance the body¹s immune functions and hold the potential for treatment and prevention of many types of cancer.
Digestive process affects anti-cancer activity of tea in gastrointestinal cells
Increased consumption of teas rich in catechins is associated with reduced risk of stomach, colon and other gastrointestinal cancers. However, the effects of digestion on the anticancer activity of tea catechins have largely been ignored. A study by nutrition researchers at The Ohio State University and Purdue University found that the digestive process could both alter the structure of the tea catechins and their anticancer activity.

News discussion:

Medicine & Health news